Compare ALTG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALTG | PRLD |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.6M | 207.5M |
| IPO Year | N/A | 2020 |
| Metric | ALTG | PRLD |
|---|---|---|
| Price | $5.17 | $3.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $11.33 | $4.67 |
| AVG Volume (30 Days) | ★ 200.0K | 195.8K |
| Earning Date | 05-06-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $5.02 | $320.10 |
| Revenue Next Year | $3.06 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $3.54 | $0.61 |
| 52 Week High | $8.88 | $4.19 |
| Indicator | ALTG | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 33.14 | 53.12 |
| Support Level | $4.57 | $2.69 |
| Resistance Level | $5.84 | $4.10 |
| Average True Range (ATR) | 0.30 | 0.32 |
| MACD | -0.09 | -0.05 |
| Stochastic Oscillator | 10.39 | 27.35 |
Alta Equipment Group Inc is an integrated equipment dealership platform in the U.S. Its segments are Material Handling, Construction Equipment, and Master Distribution. The Material Handling segment is engaged in operations related to the sale, service, and rental of lift trucks in Michigan, Illinois, Indiana, New York, Virginia, and throughout the New England states whereas, the Construction Equipment segment is principally engaged in operations related to the sale, service, and rental of construction equipment in Michigan, Indiana, Illinois, Ohio, Pennsylvania, New York, Florida and throughout the New England States, and The Master Distribution segment is engaged in environmental processing equipment distribution with sub dealers throughout the United States and Canada.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.